ClinicalTrials.gg
CompletedNCT02810964Updated Jul 27, 2021Results posted

Sulforaphane to Reduce Symptoms of Schizophrenia

A Phase 2 interventional study of Sulforaphane Nutraceutical and Identical-appearing Placebo in Schizophrenia and Schizoaffective Disorder, sponsored by Sheppard Pratt Health System. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-27.

Sponsored by Sheppard Pratt Health System · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,466 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
670th of 1,320
64 · median 66
Started
2017
with 48 others
Phase 2
217 of 1,466
11 open now
Registered
962nd of 1,466
by date

Among the 1,466 studies in Schizophrenia with a site in United States, this one is the 670th largest by enrollment of the 1,320 interventional ones that give a count, is one of 49 that started in 2017, is one of 217 in phase 2, and was the 962nd registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,466 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,466 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if taking a sulforaphane nutraceutical versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder

Keywords

  • Schizophrenia
  • Schizoaffective Disorder
  • Sulforaphane
  • Sulforaphane supplement
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capacity for written
  • Age 18-65 years, inclusive
  • , 5th Edition (DSM-5) diagnosis of schizophrenia or schizoaffective disorder as determined by the Structured Clinical Interview for DSM-5 Disorders (SCID-5)
  • Currently an outpatient at time of screening
  • Residual psychotic symptoms of at least moderate severity as evidenced by a Positive and Negative Syndrome Scale (PANSS) total score of 60 or higher AND one or more of the following: one or more PANSS positive symptom scores of 4 or higher; OR containing at least three positive or negative items with scores of 3 or higher at the screening visit
  • Receiving antipsychotic medication for at least 8 weeks prior to enrolling in the study with no antipsychotic medication changes within the previous 21 days from visit 2 (week 0)
  • Conformance to PORT Treatment Recommendation about Maintenance Antipsychotic Medication Dose
  • Proficient in the English language
  • Participated previously in one of our screening studies

Exclusion criteria

Exclusion Criteria:

  • Any or unstable medical disorder as determined by the principal investigator and/or the study physician (e.g., infection or other immunodeficiency condition (such as receiving chemotherapy), uncontrolled diabetes, congestive heart failure)
  • diagnosis of intellectual disability or comparable diagnoses determined by previous versions of the DSM
  • DSM-5 diagnosis of a moderate or severe substance use disorder, except for caffeine or tobacco, within the last three months prior to the screening visit. If the patient has a positive drug toxicity screen at the time of visit 1 (screening), further evaluation by the investigator will be done of the substance use to determine eligibility.
  • Any current use of a broccoli supplement (e.g., Avmacol® or other health food broccoli supplement)
  • Participated in any drug trial in the past 30 days prior to the screening visit
  • Pregnant, planning to become pregnant, or breastfeeding during the study period
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Sulforaphane Nutraceutical

    The sulforaphane nutraceutical contains inactive glucoraphanin, a glucosinolate from broccoli seeds, and myrosinase from broccoli sprouts. The ingestion of this compound leads to the hydrolysis of glucoraphanin, the generation of sulforaphane within the gastrointestinal (GI) tract, and the subsequent systemic absorption of the sulforaphane. The dose per tablet is 16 mg of glucoraphanin or 37 µmol; 6 tablets per day should yield about 100 µmol of sulforaphane. The tablets, which will be swallowed, are provided as .375 punch size, round concave tablets. In this arm, the participant will take 6 tablets of the sulforaphane nutraceutical daily for 16 weeks after a 2-week placebo run-in.

    Drug: Sulforaphane Nutraceutical

  • Placebo comparator
    Identical-appearing Placebo

    The inert compound placebo looks identical to the sulforaphane nutraceutical. In this arm, the participant will take 6 tablets of the placebo daily for 16 weeks after a 2-week placebo run-in.

    Drug: Identical-appearing Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase

    The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale.

    Time frame: 16 weeks (week 2 to week 18)

Secondary outcomes

  1. Change in MATRICS Consensus Cognitive Battery (MCCB) Overall Composite Scores From the Start to the End of the Study

    The MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB) is a standardized battery of 10 tests that measure 7 domains of cognitive performance: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Overall composite t-scores are calculated using scores from all subtests. A t-score of 50 (10) is the mean (standard deviation) of the relevant reference population. Higher values indicate better performance.

    Time frame: 18 weeks (week 0 to week 18)

  2. Change in C-Reactive Protein From the Start to the End of the Study

    Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)

  3. Change in Pentraxin-3 From the Start to the End of the Study

    Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)

  4. Change in Anti-Saccharomyces Cerevisiae IgA Class Antibodies From the Start to the End of the Study

    Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)

  5. Change in Interleukin-6 From the Start to the End of the Study

    Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)

  6. Change in Tumor Necrosis Factor - Alpha From the Start to the End of the Study

    Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)

  7. Change in Interferon Gamma From the Start to the End of the Study

    Time frame: 18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)

07

Results

Posted Jul 27, 2021

Participant flow

We enrolled n=64 participants drawn from rehabilitation and treatment programs in Central Maryland. Dates of recruitment: February 2017 - June 2019.

Placebo Run-In Phase (2 Weeks)
Participant flow — Placebo Run-In Phase (2 Weeks)
MilestoneSulforaphane NutraceuticalIdentical-appearing Placebo
Started3232
Completed3232
Not completed00
Double-Blind Treatment Phase (16 Weeks)
Participant flow — Double-Blind Treatment Phase (16 Weeks)
MilestoneSulforaphane NutraceuticalIdentical-appearing Placebo
Started3232
Completed2929
Not completed33
Withdrew: Withdrawal by subject12
Withdrew: Lost to follow-up10
Withdrew: Protocol violation01
Withdrew: Relocation10

Outcome measures

PrimaryChange in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase

The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale.

Time frame:
16 weeks (week 2 to week 18)
Reported as:
Mean · score on a scale
Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase
score on a scaleSulforaphane NutraceuticalIdentical-appearing Placebo
Wk 2 (Begin Treatment) PANSS Total Score81.0 ± 12.281.5 ± 13.0
Wk 18 (End Treatment) PANSS Total Score81.7 ± 13.379.7 ± 14.6
SecondaryChange in MATRICS Consensus Cognitive Battery (MCCB) Overall Composite Scores From the Start to the End of the Study

The MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB) is a standardized battery of 10 tests that measure 7 domains of cognitive performance: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Overall composite t-scores are calculated using scores from all subtests. A t-score of 50 (10) is the mean (standard deviation) of the relevant reference population. Higher values indicate better performance.

Time frame:
18 weeks (week 0 to week 18)
Reported as:
Mean · t scores
Change in MATRICS Consensus Cognitive Battery (MCCB) Overall Composite Scores From the Start to the End of the Study
t scoresSulforaphane NutraceuticalIdentical-appearing Placebo
Wk 0 (Baseline) MCCB Score25.0 ± 12.019.5 ± 13.4
Wk 18 (End Treatment) MCCB Score26.8 ± 12.622.8 ± 13.6
SecondaryChange in C-Reactive Protein From the Start to the End of the Study
Time frame:
18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Reported as:
Mean · ng/ml
Change in C-Reactive Protein From the Start to the End of the Study
ng/mlSulforaphane NutraceuticalIdentical-appearing Placebo
CRP (Wk 0, Baseline)10402.8 ± 13488.28969.7 ± 9021.6
CRP (Wk 18, End Treatment)10198.5 ± 12110.910224.5 ± 13654.0
SecondaryChange in Pentraxin-3 From the Start to the End of the Study
Time frame:
18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Reported as:
Mean · ng/ml
Change in Pentraxin-3 From the Start to the End of the Study
ng/mlSulforaphane NutraceuticalIdentical-appearing Placebo
Pentraxin(Wk 0, Baseline)0.414 ± 0.5340.461 ± 0.603
Pentraxin (Wk 18, End Treatment)0.394 ± 0.5690.558 ± 0.695
SecondaryChange in Anti-Saccharomyces Cerevisiae IgA Class Antibodies From the Start to the End of the Study
Time frame:
18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Reported as:
Mean · units/ml
Change in Anti-Saccharomyces Cerevisiae IgA Class Antibodies From the Start to the End of the Study
units/mlSulforaphane NutraceuticalIdentical-appearing Placebo
ASCA IGA (Wk 0, Baseline)0.195 ± 0.2220.168 ± 0.163
ASCA IGA (Wk 18, End Treatment)0.226 ± 0.2770.176 ± 0.184
SecondaryChange in Interleukin-6 From the Start to the End of the Study
Time frame:
18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Reported as:
Mean · pg/m
Change in Interleukin-6 From the Start to the End of the Study
pg/mSulforaphane NutraceuticalIdentical-appearing Placebo
IL-6 (Wk 0, Baseline)0.623 ± 0.2470.704 ± 0.478
IL-6 (Wk 18, End Treatment)0.694 ± 0.2880.673 ± 0.357
SecondaryChange in Tumor Necrosis Factor - Alpha From the Start to the End of the Study
Time frame:
18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Reported as:
Mean · pg/m
Change in Tumor Necrosis Factor - Alpha From the Start to the End of the Study
pg/mSulforaphane NutraceuticalIdentical-appearing Placebo
TNF-a (Wk 0, Baseline)0.668 ± 0.3930.538 ± 0.211
TNF-a (Wk 18, End Treatment)0.638 ± 0.3620.520 ± 0.263
SecondaryChange in Interferon Gamma From the Start to the End of the Study
Time frame:
18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)
Reported as:
Mean · pg/m
Change in Interferon Gamma From the Start to the End of the Study
pg/mSulforaphane NutraceuticalIdentical-appearing Placebo
IFN-g (Wk 0, Baseline)0.514 ± 0.4320.456 ± 0.172
IFN-g (Wk 18, End Treatment)0.478 ± 0.3350.526 ± 0.222

Adverse events

Collected over Adverse events were collected over an 18 week period, including the 2 week placebo run-in and the 16 week double-blind treatment phase.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sulforaphane Nutraceutical0/32 (0%)2/32 (6.3%)28/32 (87.5%)
Identical-appearing Placebo0/32 (0%)5/32 (15.6%)20/32 (62.5%)
Most frequent serious events
Most frequent serious events
EventSulforaphane NutraceuticalIdentical-appearing Placebo
Schizophrenia exacerbationPsychiatric disorders2/322/32
CholecystitisGastrointestinal disorders0/321/32
Knee replacementMusculoskeletal and connective tissue disorders0/321/32
Congestive heart failureCardiac disorders0/321/32
Most frequent other events
Most frequent other events
EventSulforaphane NutraceuticalIdentical-appearing Placebo
Respiratory symptomsRespiratory, thoracic and mediastinal disorders12/329/32
Gastrointestinal symptomsGastrointestinal disorders12/326/32
Psychiatric symptomsPsychiatric disorders11/325/32
Endocrine/metabolic symptomsEndocrine disorders4/327/32
OtherGeneral disorders4/325/32
Dermatological symptomsSkin and subcutaneous tissue disorders4/320/32
Cardiovascular symptomsCardiac disorders1/323/32
Musculoskeletal painMusculoskeletal and connective tissue disorders2/323/32
Urinary symptomsRenal and urinary disorders2/323/32
Hematological symptomsBlood and lymphatic system disorders1/320/32

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Sulforaphane NutraceuticalIdentical-appearing PlaceboTotal
<=18 years000
Between 18 and 65 years323264
>=65 years000
Age, Continuous
Age, Continuous(years)Sulforaphane NutraceuticalIdentical-appearing PlaceboTotal
Mean42.7 ± 12.345.8 ± 11.744.2 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Sulforaphane NutraceuticalIdentical-appearing PlaceboTotal
Female8715
Male242549
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Sulforaphane NutraceuticalIdentical-appearing PlaceboTotal
Caucasian181634
African American141630
Region of Enrollment
Region of Enrollment(participants)Sulforaphane NutraceuticalIdentical-appearing PlaceboTotal
United States323264
08

Study locations

1 site
  • Sheppart Pratt Health System
    Towson, Maryland 21204, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Demographic, symptom, and cognitive data will be shared with the National Database for Clinical Trials Related to Mental Illness (NDCT). Access may be obtained through an approved application with the NDCT.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Nov 2019, 32 months.

Results were first posted in Jul 2021, 1 year 8 months after primary completion.

Of 44 non-industry phase 2 interventional studies under Schizophrenia, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 73. This study's 32 months is below that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2016
First posted
Jun 23, 2016
StartActual
Feb 22, 2017
Primary completionActual
Nov 11, 2019
CompletionActual
Nov 11, 2019
Results first posted
Jul 27, 2021
Last update
Jul 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02810964
Lead sponsor
Sheppard Pratt Health System
Responsible party
Faith Dickerson (Principal Investigator, Stanley Research Program, Sheppard Pratt Health System) — Principal investigator
First posted
Jun 23, 2016
Start date
Feb 22, 2017
Primary completion
Nov 11, 2019
Completion
Nov 11, 2019
Results posted
Jul 27, 2021
Last update
Jul 27, 2021

Study contacts

Faith Dickerson, PhD, MPH
principal investigator · Sheppard Pratt Health System

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Broccoli Sprout/Broccoli Seed Extract Supplement

Start the discussion